On 15th October 2018, Prof Simone Niclou, Head of the NorLux Neuro-Oncology Laboratory at LIH’s Department of Oncology and Deputy Director of the Department of Oncology, has been elected to join the Executive Board of the European Association of Neuro-Oncology (EANO), which represents medical neuro-oncology and associated research throughout Europe.
EANO is Europe’s multidisciplinary neuro-oncology organisation embodying all medical and scientific disciplines involved in the prevention, diagnosis and treatment of tumours of the central nervous system. The association is dedicated to promote advances in neuro-oncology through innovative research and concerted education and training. With more than 600 members from 70 countries, EANO enhances collaboration between related disciplines and aims at bridging science, knowledge and practice gaps in the management of malignancies of the central nervous system. Every year, the association organises an international meeting with up to 1000 participants. It also co-organises the Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) which was last held in 2017.
Prof Niclou has been a member of EANO for many years. As Head of LIH’s NorLux Neuro-Oncology Laboratory founded in 2007, her research is focused on the biology of diffuse gliomas with a special interest in glioma metabolism, tumour heterogeneity, glioma stem cells, tumour angiogenesis and invasion. Amongst other achievements, her team has been able to establish unique patient-derived mouse models for brain tumour research and has done pioneering work on glioma angiogenesis and metabolism.
Since 2014, Prof Niclou is also an Adjunct Professor at the KG Jebsen Brain Tumour Research Centre of the University of Bergen, Norway, and in 2015 she was nominated President of the Board of Directors of the Laboratoire national de santé. She has previously served on the Scientific Board of the European Association for Neuro-Oncology (EANO) and was country representative in the council of the European Association for Cancer Research (EACR). She also regularly acts in international Advisory Boards of grant awarding bodies for cancer research throughout Europe and as an invited speaker at international scientific conferences.
‘As a long-term and dedicated member of EANO I am honoured to take up a new responsibility in the Executive Board for the next two years and bring in my expertise in the field of neuro-oncology research’, states Prof Niclou.
This news item is derived from content of the EANO website.